Business
Alpha Tau Announces 100% Local Disease Control Rate and Favorable Safety Profile Observed in Alpha DaRT® Pancreatic Cancer Trials Presented at DDW 2026
- 100% local disease control rate achieved in evaluable patients in pooled analysis of two first-in-human trials of Alpha DaRT® in pancreatic adenocarcinoma - - Favorable safety profile observed, with only 8 device-associated adverse events in 7 of 26 subjects (27%), nearly all resolving within two weeks in some of the most challenging, heavily pre-treated patients in oncology - - Highly heterogeneous patient population for whom available options are extremely limited included patients ineligibl
About this update from Alpha Tau Medical Ltd.
[{"type":"image","alt":"Alpha Tau Medical Ltd.","displaySize":"","headline":null,"caption":"Alpha Tau Medical Ltd.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":215,"url":"https://media.zenfs.com/en/globenewswire.com/05605e0853ddac4177652b0fbd0afb40"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/7VgHu6alli3.BtV2lI3Eng--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTMwMQ--/https://media.zenfs.com/en/globenewswire.com/05605e0853ddac4177652b0fbd0afb40","width":300,"height":215}},"lazy":false},{"type":"text","content":"- 100% local disease control rate achieved in evaluable patients in pooled analysis of two first-in-human trials of Alpha DaRT® in pancreatic adenocarcinoma -","length":158,"tagName":"p"},{"type":"text","content":"- Favorable safety profile observed, with only 8 device-associated adverse events in 7 of 26 subjects (27%), nearly all resolving within two weeks in some of the most challenging, heavily pre-treated patients in oncology -","length":222,"tagName":"p"},{"type":"text","content":"- Highly heterogeneous patient population for whom available options are extremely limited included patients ineligible for chemotherapy as well as patients who had received up to four prior lines of chemotherapy -","length":214,"tagName":"p"},{"type":"text","content":"- Streamlined outpatient endoscopic ultrasound (EUS)-guided procedure designed for seamless integration into standard GI endoscopy workflow -","length":141,"tagName":"p"},{"type":"text","content":"- Results shared in oral presentation at DDW 2026, the first presentation of Alpha DaRT at a premier international gastroenterology conference -","length":144,"tagName":"p"},{"type":"text","content":"JERUSALEM, May 04, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced the presentation of updated pooled results from two first-in-human clinical trials of Alpha DaRT in pancreatic ductal adenocarcinoma (PDAC) at Digestive Disease Week (DDW) 2026, the world's premier international gastroenterology conference.","length":450,"tagName":"p"},{"type":"text","content":"The abstract, entitled "Updated Results of Feasibility, Safety, and Tumor Control in Two First-In-Human Trials of a Novel Alpha-Emitting Radionuclide for Pancreatic Adenoca...